Orphan tests

Cambridge Quarterly of Healthcare Ethics

Volumn 5, Issue 2, 1996, Pages 300-306

  Biesecker, Leslie G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL LABORATORY IMPROVEMENT ACT; DRUG MANUFACTURE; GENETIC COUNSELING; GENETIC DISORDER; GENETIC PROCEDURES; GENETIC SCREENING; GENETIC SERVICE; GENETICS; GENETICS AND REPRODUCTION; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; PREDICTION AND FORECASTING; PROFESSIONAL STANDARD; SOCIAL CONTROL; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL LABORATORY IMPROVEMENT ACT; GENETICS AND REPRODUCTION;

ETHICS COMMITTEES, RESEARCH; ETHICS, MEDICAL; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC RESEARCH; GENETIC SCREENING; GENETIC SERVICES; GENETIC TECHNIQUES; HUMANS; ORPHAN DRUG PRODUCTION; PREDICTIVE VALUE OF TESTS; SOCIAL CONTROL, FORMAL; UNITED STATES;

EID: 0030100124     PISSN: 09631801     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0963180100007076     Document Type: Article

References (21)

1. Collins FS, Galas D. A new five year plan for the U.S. Human Genome Project. Science 1993;262:43-6.
2. Koshland DE Jr. Ahead of schedule and on budget. Science 1994;266:199.
3. Mansfield B, Ed. Genome centers provide overview and genetic map goal met ahead of schedule. Human Genome News 1994;6:1-14.
4. Collins FS. Positional cloning moves from perditional to traditional. Natural Genetics 1995;9:347-50.
5. Thoene JG. Current status of orphan disease drug development. Current Opinions in Pediatrics 1994;6:209-12.
6. Motulsky AG. Frequency of sickling disorders in U.S. blacks. New England Journal of Medicine 1973;288:31.
7. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The Metabolic and Molecular Basis of Inherited Disease, Vol 3. New York: McGraw-Hill, 1995:3848.
8. Biesecker LG, Graham JM Jr. Syndrome of the month: Pallister-Hall syndrome. Journal of Medical Genetics [Submitted].
9. Beaudet AL. Aspartoacylase deficiency (Canavan disease). In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The Metabolic and Molecular Basis of Inherited Disease, Vol 3. New York: McGraw-Hill, 1995:4599-605.
10. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG. Laboratory issues in human genetics. In: Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, Eds. Assessing Genetic Risk: Implications for Health and Social Policy. Washington, DC: National Academy Press, 1994:116-45.
11. Biesecker LG. Commentary. Cambridge Quarterly of Healthcare Ethics 1995;4:389-92.
12. See note 5. Thoene. 1994;6:209-12.
13. Asbury CH. Evolution and current status of the Orphan Drug Act. International Journal of Technological Assessment of Health Care 1992;8:573-82.
14. Coster JM. Recombinant erythropoietin. Orphan product with a silver spoon. International Journal of Technological Assessment of Health Care 1992;8:635-46.
15. See note 5. Thoene. 1994;6:209-12.
16. MacKay CR. Developing a test to detect carriers of Huntington's disease. IRB A Review of Human Subjects Research 1984;6:1-5.
17. See note 10. Andrews et al. 1994:116-45.
18. Federal Register. Federal Register 57(60491). 1992.
19. Federal Register. Federal Register 57(40). 1992.
20. See note 10. Andrews et al. 1994:116-45.
21. Popovich B. Private communication. 1995.